Drug Safety

Drug Safety (commonly abbreviated as ''Drug Saf.', CODEN DRSAEA) is an international peer-reviewed monthly journal in pharmacovigilance published by Adis International, and is the official journal of the International Society of Pharmacovigilance (ISoP), with manuscripts published in English.Drug Safety（常用缩写 Drug Saf.，CODEN 为 DRSAEA）是一份由 Adis International 出版的药物警戒领域国际同行评审月刊，常缩写 Drug Saf.，现为国际药物警戒学会（International Society of Pharmacovigilance，ISoP）的官方刊物，稿件以英文为主。

Scope

According to the aims and scope published by the publisher, the journal covers pharmacovigilance, pharmacoepidemiology, benefit-risk assessment, risk management and medication error prevention, and advances the rational use of pharmacotherapy by publishing reviews and original research articles offering guidance for safe and effective drug utilization and prescribing.根据出版方公布的收录说明，该刊覆盖药物警戒、药物流行病学、获益—风险评价、风险管理与用药差错预防等领域，并通过综述与原创研究推动药物疗法的合理使用，为安全有效的用药与处方提供指导。^[1]

• Overviews of contentious or emerging issues: overviews addressing questions in pharmacovigilance that remain unsettled or are newly emerging.争议与新兴议题综述： 针对药物警戒领域尚无定论或正在形成的新问题，刊发概览性评论与立场文章。
• Comprehensive narrative reviews: an authoritative source of information on the epidemiology, clinical features, prevention and management of adverse effects of individual drugs and drug classes.全面叙述性综述： 就单种药物或某一药物类别的不良反应，就流行病学、临床特征、预防与管理提供权威性的资料来源。
• In-depth benefit-risk assessment: in-depth assessment of adverse effect and efficacy data for a drug within a defined therapeutic area.获益—风险评价： 针对特定治疗领域中的某一药物，就其不良反应与疗效数据展开深入评估。
• Systematic reviews: systematic reviews with or without meta-analyses that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement.系统综述与荟萃分析： 遵循 PRISMA 声明所列的明确系统方法，汇集实证证据以回答具体研究问题。
• Original research articles: reports of well-designed studies in pharmacoepidemiology, pharmacovigilance, pharmacology, toxicology and pharmacogenomics.原创研究论文： 刊发药物流行病学、药物警戒、药理学、毒理学与药物基因组学等学科中设计良好的研究报告。
• Editorials and commentaries: editorials and commentaries on topical issues, together with letters to the editor.社论与评论： 就时事性议题刊发社论与评论，并欢迎投稿致编辑函。

As a hybrid journal, Drug Safety does not charge authors to publish via the traditional subscription-based route, but offers the option of open-access publication should authors wish it or their funders require it, and all manuscripts are subject to peer review by international experts.作为混合出版期刊，该刊沿传统订阅路线刊文不向作者收费，同时允许作者自愿或依资助方要求选择开放获取发表，稿件一律经国际同行专家评审。

History

• 1986: the journal was founded in New Zealand, initially as Medical Toxicology, with its editorial base in Auckland, as one of the pharmacology journals in the Adis International series.1986年： 期刊在新西兰创刊，初名 '''Medical Toxicology''`，主编社址设于奥克兰，是 Adis International 旗下药理系列期刊之一。
• 1987: it was renamed Medical Toxicology and Adverse Drug Experience, shifting its emphasis from toxicology alone toward adverse drug reactions.1987年： 更为 Medical Toxicology and Adverse Drug Experience，刊名重心由单纯的毒理学转向药物不良反应。
• 1990: it obtained its current title, Drug Safety, which it has retained since, becoming a principal international journal in pharmacovigilance.1990年： 改用现名 Drug Safety，此后长期沿用，成为药物警戒领域的主要国际期刊。
• Society affiliation and publisher: the journal is now the official publication of the International Society of Pharmacovigilance, is edited and published by Adis International, sits within the Springer Healthcare brand of Springer Nature, and is hosted on the SpringerLink platform.学会合作与出版方： 期刊现为国际药物警戒学会的官方刊物，由 Adis International 编辑出版，归属 Springer Nature 旗下 Springer Healthcare 品牌，在线平台为 SpringerLink。
• Indexing and ranking: the journal is indexed in SCIE and classified in JCR under pharmacology in the Q1 quartile. In the Chinese Academy of Sciences journal ranking it places in the second tier of the medical sciences major, and the latest evaluation records no warning.收录与分区： 期刊被 SCIE（科学引文索引扩展版）收录，JCR 学科分类为药理学，位列 Q1；在中国科学院期刊分区中位于医学大类 2 区，最新评估未见预警记录。

Editors

The journal is led by a single Editor-in-Chief supported by an international editorial board. Manuscripts undergo peer review by international experts, acceptance is decided by the Editor-in-Chief, and day-to-day editorial work is handled by the Adis International team in Auckland.期刊设主编一人，另配有多国编委，稿件经国际同行评审后由主编决定录用，编辑部日常事务由 Adis International 在奥克兰的团队承担。

• Nitin Joshi (BPharm, PGDipPharm, MRSNZ, FISoP) has served as Editor-in-Chief since 2012 and is responsible for the journal's overall academic direction and acceptance decisions.Nitin Joshi（BPharm，PGDipPharm，MRSNZ，FISoP）：自 2012 年起担任该刊主编，负责整体学术方向与录用决策。
• Society representative: Dr Omar Aimer, President of the International Society of Pharmacovigilance, serves as the Society's official representative on the journal's board.学会官方代表： 由国际药物警戒学会会长 Omar Aimer 博士出任该刊理事会的官方代表，沟通学会与出版方之间的编辑事务。
• Board composition: the formal editorial board brings together international scholars in pharmacovigilance, clinical pharmacology and epidemiology, including researchers based in the United States, the Netherlands, the United Kingdom, Australia and Italy.编委构成： 正式编委涵盖药物警戒、临床药理学与流行病学领域的国际学者，包括来自美国、荷兰、英国、澳大利亚与意大利等国的研究者。
• The full editorial board and submission requirements are listed on the journal's official website.完整编委会名单与投稿要求见期刊官网。^[2]